On the afternoon of December 2, 2022, the release and interpretation meeting of the 2022 edition of the "Guidelines for the Diagnosis and Treatment of Psoriasis in China" was successfully held online and offline. L'Oreal (China) Co., Ltd. Xerox brand supports the organization. The guideline was co-written by 31 well-known experts of traditional Chinese and Western medicine organized by the Psoriasis Special Committee of the Dermatology Branch of the Chinese Medical Association. The characteristic psoriasis diagnosis and treatment guidelines standardize the diagnosis and treatment of psoriasis by dermatologists, further improve and update the new evidence-based medical evidence for psoriasis diagnosis and treatment, keep up with the international frontier, and let more good drugs benefit Chinese psoriasis patients .

Figure 1 Guide release site

Figure 2  The guideline conference was hosted by the director of the Psoriasis Research Center of the Dermatology Branch of the Chinese Medical Association

Professor Sun Liangdan hosted

First of all, the Executive Committee of the International Psoriasis Council (IPC) and the Asia-Pacific Coordinator of the WHO Global Psoriasis Surveillance Program (GPA), the Director of the Psoriasis Committee of the Dermatology and Venereology Branch of the Chinese Medical Association, and the Guidelines for the Diagnosis and Treatment of Psoriasis in China "Professor Zhang Xuejun, chairman of the editorial committee of the guideline, delivered a speech on the release of this version of the guideline and released a new version of the guideline. Professor Zhang Xuejun pointed out that the editorial board of the 2022 guideline is an authoritative expert in the field of psoriasis in my country, including three generations of old, middle-aged and young people. The content and length of this edition of the guidelines are basically consistent with the 2018 edition. The main revisions have been made in the following aspects. The first is to revise the definition of psoriasis, which is a chronic, relapsing, inflammatory, and systemic disease, incorporating the latest international guidelines. Classification of psoriasis, paying more attention to psoriasis comorbidity, adding imaging diagnosis in psoriasis diagnosis, updating new biologics and small molecule targeted drugs for psoriasis, emphasizing psoriasis prevention and the importance of skin barrier repair, highlighting the characteristics of integrated traditional Chinese and Western medicine in the treatment of psoriasis, and will publish an English version of the guide. It is hoped that in the next 5 years, the new version of the guide will provide more detailed, scientific and up-to-date information for dermatologists across the country. Guidance and reference, strive to achieve a 90% clinical cure rate for psoriasis, and better implement the spirit of the 20th National Congress and the Healthy China Strategy.

Figure 3 Professor Zhang Xuejun

Professor Furen Zhang from Shandong First Medical University, deputy director of the compilation of "Guidelines for the Diagnosis and Treatment of Psoriasis in China", introduced the process of writing and revising the new edition of the guidelines. and perfect. In July 2021, the first symposium on compiling the guidelines for the diagnosis and treatment of psoriasis in China (2022 edition) was held in Suzhou; Compiled; during May-June 2022, two mid-term seminars were held to further discuss the content of the guideline revision. In August 2022, a guideline finalization meeting was held in Suzhou, and today the guideline was officially released at the 6th China Psoriasis Conference. release. The entire writing process is rigorous and orderly, and it is the crystallization of the wisdom of each expert. It is believed that the release and promotion of the new version of the guideline can further guide the standardized diagnosis and treatment of psoriasis in clinical practice.

Figure 4 Professor Zhang Furen

Professor Zhang Xibao, deputy director and secretary-general of the compilation of "Guidelines for Diagnosis and Treatment of Psoriasis in China" and Professor Zhang Xibao from the Institute of Dermatology of Guangzhou Medical University, interpreted this edition of the guidelines in detail. . Compared with the 2018 edition, a new chapter on methodology has been added, psoriasis dichotomy has been introduced, and in auxiliary diagnosis, images such as X-ray, computerized tomography (CT), and magnetic resonance (MRI) detection have been added The content of medical science has further enriched and perfected the concept of psoriasis comorbidities. Supplement the latest development of biological agents in recent years, increase the combined use of biological agents, improve and optimize the traditional Chinese medicine treatment, increase the psychological treatment of psoriasis, including according to NEI (neuro-endocrine-immune network) and psoriasis mental-psychological disorders , prophylaxis combined with pathogenesis is proposed. Through the joint efforts of all experts, they have contributed to the standardization and scientificization of psoriasis diagnosis and treatment in China, and affirmed the hard work of the guideline writing secretary group.

Figure 5 Professor Zhang Xibao

31 guideline editorial board members from all over the country participated in the "Chinese Psoriasis Diagnosis and Treatment Guidelines" (2022 Edition) release and interpretation meeting through a combination of online and offline methods. It is reported that this version of the guidelines has been submitted to the Chinese Journal of Dermatology. The release of the new guidelines will further standardize the diagnosis and treatment of psoriasis by dermatologists, promote the integration of my country's psoriasis diagnosis and treatment with the world, and benefit millions of psoriasis patients in China.